The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT ...

Under the partnership with RadioMedix, AlphaMedix has reached Phase 2 testing, but the results so far are being discussed with the FDA for a potential regulatory submission. In September ...

Sanofi already has an exclusive licence with OranoMed and its US partner RadioMedix to develop a drug using radioactive lead isotopes for neuroendocrine tumours, a rare cancer affecting cells that ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

This agreement follows Sanofi’s announcement of an exclusive licensing agreement with Orano Med and RadioMedix to advance RLTs in rare cancers with a focus on one late-stage project, AlphaMedix™.

setting up rivalry with Novartis Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to ...

The deal comes just one month after Sanofi, Orano Med and RadioMedix entered into an exclusive licensing agreement worth €320m, also to advance RLTs for rare cancers. The September agreement centres ...

This agreement follows Sanofi’s announcement of an exclusive licensing agreement with Orano Med and RadioMedix to advance radioligand therapies (RLTs) in rare cancers with a focus on one late ...